
Annual report 2025
added 04-25-2026
Evogene Ltd. EPS Ratio 2011-2026 | EVGN
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Evogene Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | -0.83 | -0.7 | -0.81 | -0.81 | -0.77 | -0.68 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.68 | -0.83 | -0.767 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
2.1 | $ 21.87 | 2.15 % | $ 1.02 B | ||
|
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | ||
|
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M | ||
|
Aptorum Group Limited
APM
|
-0.19 | $ 0.9 | - | $ 6.62 M | ||
|
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
1.51 | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
1.37 | $ 22.28 | 1.46 % | $ 3.69 B | ||
|
Advaxis
ADXS
|
-7.99 | - | -9.65 % | $ 45.9 M | ||
|
AIkido Pharma
AIKI
|
-1.57 | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
-2.14 | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
-2.85 | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-10.7 | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-1.11 | - | -2.5 % | $ 5.88 M | ||
|
Applied Therapeutics
APLT
|
-1.42 | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
-0.96 | - | -39.0 % | $ 4.57 M | ||
|
AgeX Therapeutics
AGE
|
-1.91 | - | -10.17 % | $ 12.2 K | ||
|
Aravive
ARAV
|
-2.1 | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
-1.62 | - | 17.91 % | $ 11.1 M | ||
|
BioNTech SE
BNTX
|
42.2 | $ 105.26 | -0.19 % | $ 27.2 B | ||
|
Avenue Therapeutics
ATXI
|
-0.93 | - | -52.27 % | $ 4.45 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
-0.78 | $ 4.1 | 0.37 % | $ 438 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-0.13 | $ 23.98 | 3.07 % | $ 3.05 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.46 | - | - | $ 7.46 M | ||
|
Autolus Therapeutics plc
AUTL
|
-1.08 | $ 1.47 | 1.74 % | $ 391 M | ||
|
Aptose Biosciences
APTO
|
-10.4 | - | -45.71 % | $ 1.2 M | ||
|
AstraZeneca PLC
AZN
|
0.08 | - | - | $ 96.9 B | ||
|
AVROBIO
AVRO
|
0.27 | - | 1083.1 % | $ 745 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-5.97 | $ 2.98 | 2.41 % | $ 4.91 M | ||
|
BioDelivery Sciences International
BDSI
|
0.85 | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
0.2 | - | 0.49 % | $ 251 B | ||
|
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
-2.21 | - | - | $ 867 M | ||
|
bluebird bio
BLUE
|
-1.93 | - | - | $ 546 M | ||
|
ContraFect Corporation
CFRX
|
-125 | - | -5.16 % | $ 5.39 M | ||
|
Cardiff Oncology
CRDF
|
-0.69 | $ 1.72 | - | $ 115 M | ||
|
BioXcel Therapeutics
BTAI
|
-5.73 | $ 1.1 | 3.76 % | $ 13.4 M | ||
|
Cabaletta Bio
CABA
|
-2.1 | $ 2.97 | 0.68 % | $ 298 M | ||
|
Cara Therapeutics
CARA
|
-2.46 | - | -3.03 % | $ 260 M | ||
|
Allena Pharmaceuticals
ALNA
|
-0.72 | - | 3.16 % | $ 1.9 M | ||
|
CASI Pharmaceuticals
CASI
|
-0.27 | - | - | $ 35.4 M | ||
|
CymaBay Therapeutics
CBAY
|
-0.99 | - | - | $ 3.45 B |